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disease severity (mildly ill, moderately ill, and severely ill). Treatment 
parameters are estimated using published information for once-daily risperidone 
standard oral therapy (RIS-SOT) and once-monthly risperidone long-acting 
injection (RIS-LAI) with LFA therapy characteristics derived from observed study 
trends. One-year and five-year results are expressed as discounted direct 
medical costs and mean number of relapses per patient (inpatient, outpatient, 
total) and are estimated for LFA therapies given at three, six, and nine month 
intervals. RESULTS: The one-year results show that LFA therapy every 3 months 
(LFA-3) ($6,088) is less costly than either RIS-SOT ($10,721) or RIS-LAI ($9,450) 
with similar trends in the 5-year results. Moreover, the model predicts that LFA-3 
versus RIS-SOT versus RIS LAI therapy will reduce costly inpatient relapses (0.16 
vs. 0.51 vs. 0.41). Extending the interval to six (LFA-6) and nine (LFA-9) months 
resulted in further reductions in relapse and costs. Limitations include the fact 
that LFA therapeutic options are hypothetical and do not yet exist and limited 
applicability to compare one antipsychotic agent versus another as only 
risperidone therapy is evaluated. CONCLUSIONS: These study results have 
quantified the potential health state improvements and potential direct medical 
cost savings achievable with the development and use of LFA medication 
delivery technologies.  
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OBJECTIVES: To examine the circumstances of the recognition of the autism, the 
problems in connection with the condition of the child as well as the 
opportunities, deficiencies of the support. METHODS: During the research as the 
first step the Autistic Association and its member organizations were selected. 
As the second step the families were reached through them. A total of 358 postal 
examinational questionnaires were sent; the interviewers visited 312 families. 
During my analysis the data of the samples between year 0-18 were used (276 
people). The process of the data was completed by SPSS program. RESULTS: The 
first symptoms of autism are perceived foremost by the parents that is followed 
by an at least 2 years period till the diagnosis. Only 30% of the children speak 
well, only 59% of the parents always understand them. The 38% of children have 
slight or severe insomnia. A total of 84% of the children have frequent or 
permanent behavioural disorders. Due to the child’s autism the families are 
isolated; 40% of the parents have been unemployed since the birth of their child. 
The assistance or communication between the concerned families is incidental 
(5%). The 36% of the parents experienced discrimination in the field of health 
care. The care of people with disabilities lacks from the health visitors’ graduate 
training that makes early recognition and the care more difficult. 
CONCLUSIONS: There is no comprehensive strategy in Hungary for the solution 
of the problems of the families raising autistic children. Developing a filtering 
system is necessary which would decrease the time span between the 
recognition and the diagnose. Our other goal is to build a comprehensive training 
system to broaden the knowledge of the health professionals.  
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OBJECTIVES: To evaluate the impact on alcohol-dependent patients’ reported 
outcomes (PROs) from the as-needed use of nalmefene versus placebo in 
reduction of alcohol consumption. METHODS: Two 6-month randomized, 
double-blind, placebo-controlled, efficacy studies assessing nalmefene 18mg 
(base) were conducted in Europe (ESENSE 1 [NCT00811720]; ESENSE 2 
[NCT00812461]). All patients took part in a motivational intervention (BRENDA) to 
support behavioural change and adherence to treatment. The Short Form Health 
Survey (SF-36), the EuroQol-5 Dimensions (EQ-5D) and the Drinker Inventory of 
Consequences (DrInC-2R) questionnaires were administered at baseline, weeks 
12 and 24. Post-hoc analyses of the pooled subgroup of patients with a high 
drinking risk level (men:>60 g/day; women:>40 g/day) assessed change from 
baseline using mixed models repeated measures. RESULTS: At baseline, the 
sample comprised 641 patients: 322 in the placebo group, 319 in the nalmefene 
group. The SF-36 Mental Component Score (MCS) and the EQ-5D health state 
score were 40.9±12.6 and 67.9±17.2 in the placebo group; 40.9±11.9 and 68.9±17.7 
in the nalmefene group. The MCS improvement at week 24 was significantly 
correlated to HDD (Heavy Drinking Day) and TAC (Total Alcohol Consumption) 
reduction and was significantly larger for the nalmefene group compared to 
placebo (p=0.0008): the means change from baseline were 5.74±0.79 and 2.65±0.78 
in the nalmefene and placebo groups respectively. For the EQ-5D, the mean 
change from baseline for nalmefene compared to placebo for the health state 
score and the utility index score was 3.46 (p=0.0124) and 0.03 points (p=0.0445) 
respectively. The mean DrInC-2R total score change from baseline to week 24 
was significantly correlated to HDD and TAC reduction. The improvement, 
indicating less alcohol-related problems, was significantly larger with nalmefene 
(17.86±1.31) than for placebo (14.64±1.30) (p=0.0292). CONCLUSIONS: As-needed 
use of nalmefene for reduction of alcohol consumption leads to statistically 
significantly larger improvements of alcohol dependent patients' PROs versus 
placebo.  
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OBJECTIVES: Complete qualitative concept elicitation (CE) and cognitive 
interviews leading to preliminary development of a patient-reported outcome 
(PRO) measure to assess treatment benefit in major depressive disorder (MDD) 
clinical trials. METHODS: Qualitative interviews were conducted with adult MDD 
patients in the US who recently experienced a major depressive event. All 
participants had a Hamilton Depression Rating Scale (HAM-D) total score >18 at 
screening. Experienced interviewers conducted CE and cognitive interview 
sessions using semi-structured interview guides. The CE interview guide was 
used to elicit spontaneous reports of symptom experiences along with probing to 
further explore and confirm concepts. The cognitive interview guide was 
developed to evaluate concept relevance, understandability, and structure of the 
draft items, and to facilitate further instrument refinement. All interview 
sessions were audio recorded and transcribed. The CE interviews were coded for 
qualitative content analysis using Atlas.ti, and the cognitive interview 
transcripts were summarized in cognitive report tables. RESULTS: Forty patients 
[mean age: 46.2; 67.5% female; 45.0% white (non-Hispanic)] participated in the CE 
interviews. Mean (SD) HAM-D total score of the participants was 24.4 (4.3). A total 
of 3,022 symptom codes, representing 91 different concepts were derived from 
the transcripts. Data from the CE interviews was considered alongside existing 
literature and clinical expert opinion during an item-generation meeting, leading 
to development of a 36-item measure with a 5-point response scale. 
Subsequently, fifteen patients participated in three waves of cognitive 
interviews, during which, one item was removed and four others were modified. 
CONCLUSIONS: The S-MDD is a 35-item PRO measure intended for use as an 
endpoint in MDD clinical trials to support medical product labeling. It was 
developed in accordance with the FDAs PRO Guidance and best practices. 
Qualitative interviews have provided evidence for content validity. Future 
quantitative studies will confirm the S-MDD’s measurement properties and 
support FDA qualification.  
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Citalopram (Celexa®) is in the selective serotonin reuptake inhibitor (SSRI) class 
of antidepressants. It is taken orally. Citalopram has been linked to both QT 
prolongation and Torsade de pointes (TdP), and these risks may be dose related. 
OBJECTIVES: To analyze the association between QT prolongation and TdP 
adverse events and the utilization of citalopram and other SSRIs. METHODS: 
This retrospective, descriptive study used the U.S. FDA Adverse Event Reporting 
System (FAERS) database. The database included 7,840,225 adverse events 
associated with SSRI drugs from 1997 fourth quarter to 2011 third quarter. The 
number of reported QT-prolongation and TdP cases associated with each study 
drug was calculated over time. Furthermore, for each case, dosage of the drug, 
when available in the report, was noted. RESULTS: A total of 1192 reported cases 
of QT prolongation and TdP were associated with SSRI drugs over the 14-year 
study period. Only 18% (219) of the adverse event reports were related 
specifically to citalopram, while the rest were related to other SSRI drugs. There 
were 911 reports for women, 252 for men, and 29 reports without gender 
information. The rate of QT prolongation and TdP associated with dosages of 20 
mg, 40 mg, and 60 mg of citalopram per day were 39%, 21%, and 2%, respectively. 
However, the percentage of reports without dosage information was 37%, so we 
were unable to draw any conclusions regarding dosage-related events. 
CONCLUSIONS: The results confirmed an association between the use of 
citalopram with QT prolongation and TdP. Furthermore, the association was not 
limited to citalopram alone but was widespread across the SSRIs. There were 
more adverse events observed for women than for men. Dose dependency was 
not established in this study. Future studies are warranted.  
 
PMH48  
USING TRANSLATABILITY ASSESSMENT TO REFINE A PATIENT- REPORTED 
OUTCOME (PRO) MEASURE DURING THE DEVELOPMENT PROCESS  
Martin ML1, McCarrier KP1, Basse SJ1, Ramasamy A2, Mathews M2, Bush EN3, Greco N4 
1Health Research Associates, Inc., Seattle, WA, USA, 2Forest Research Institute, Jersey City, NJ, 
USA, 3Eli Lilly and Company, Indianapolis, IN, USA, 4AbbVie Inc, North Chicago, IL, USA  
OBJECTIVES: To show how translatability assessment during the patient-
reported outcome (PRO) measure development process can be used to identify 
areas where wording changes are needed to improve and refine the measure. 
METHODS: A translatability assessment was conducted on a new 35-item PRO 
measure called Symptoms of Major Depressive Disorder (S-MDD) for evaluating 
treatment benefits in MDD. Five different languages were selected (French, 
Spanish, German, Chinese, and Russian). Each PRO item was reviewed and 
assigned a difficulty rating between 1 (no difficulty) and 5 (extreme difficulty) by 
an experienced translation consultant in each language. The difficult concepts 
for translation were compared to the problematic items for patient 
comprehension (from cognitive interviews) to identify difficult items for both 
translation and patient comprehension. RESULTS: Three items of the 35-item S-
MDD showed difficulty in patient comprehension and in the ability to accurately 
translate the concept. Due to the convergence of these two problematic findings 
during the PRO development, the item “how difficult was it for you to keep your 
mind free of worrying thoughts?” was changed to “how difficult was it for you to 
